Brian Skorney
Stock Analyst at Baird
(3.73)
# 779
Out of 5,090 analysts
119
Total ratings
46.43%
Success rate
9.91%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $13.43 | +63.81% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $22.26 | -32.61% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $46.67 | +32.85% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.55 | +444.50% | 4 | Aug 12, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $51.37 | +135.55% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $20.28 | +57.79% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $181.30 | +40.65% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $718.36 | -18.29% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $68.48 | -19.68% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $121.22 | -17.51% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $13.58 | +120.91% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $0.22 | +2,208.40% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $14.60 | +36.99% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $11.12 | +124.82% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $329.89 | -34.83% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $155.51 | +15.75% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $9.35 | +199.47% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $13.16 | +196.35% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $45.01 | +39.97% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $455.48 | -28.65% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $22.84 | -56.22% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $4.33 | +6,135.57% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.28 | +40.19% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.35 | +22,122.22% | 3 | May 7, 2018 |
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $13.43
Upside: +63.81%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $22.26
Upside: -32.61%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $46.67
Upside: +32.85%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.55
Upside: +444.50%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $51.37
Upside: +135.55%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $20.28
Upside: +57.79%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $181.30
Upside: +40.65%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $718.36
Upside: -18.29%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $68.48
Upside: -19.68%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $121.22
Upside: -17.51%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.58
Upside: +120.91%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.22
Upside: +2,208.40%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $14.60
Upside: +36.99%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $11.12
Upside: +124.82%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $329.89
Upside: -34.83%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $155.51
Upside: +15.75%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $9.35
Upside: +199.47%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $13.16
Upside: +196.35%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $45.01
Upside: +39.97%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $455.48
Upside: -28.65%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $22.84
Upside: -56.22%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $4.33
Upside: +6,135.57%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.28
Upside: +40.19%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.35
Upside: +22,122.22%